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ABSTRACT 
Understanding how tumours develop resistance to chemotherapy is a major issue in 
oncology. When treated with temozolomide (TMZ), an oral alkylating chemotherapy drug, 
most low-grade gliomas (LGG) show an initial volume decrease but this effect is rarely long 
lasting. In addition, it has been suggested that TMZ may drive tumour progression in a subset 
of patients as a result of acquired resistance. Using longitudinal tumour size measurements 
from 121 patients, the aim of the present study was to develop a semi-mechanistic 
mathematical model to determine whether resistance of LGG to TMZ was more likely to 
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result from primary and/or from chemotherapy-induced acquired resistance that may 
contribute to tumour progression. We applied the model to a series of patients treated upfront 
with TMZ (n = 109) or PCV (procarbazine, CCNU, vincristine) chemotherapy (n=12) and 
used a population mixture approach to classify patients according to the mechanism of 
resistance most likely to explain individual tumour growth dynamics. Our modelling results 
predicted acquired resistance in 51 % of LGG treated with TMZ. In agreement with the 
different biological effects of nitroso-ureas, none of the patients treated with PCV were 
classified in the acquired resistance group. Consistent with the mutational analysis of 
recurrent LGG, analysis of growth dynamics using mathematical modelling suggested that in 
a subset of patients, TMZ might paradoxically contribute to tumour progression as a result of 
chemotherapy-induced resistance. Identification of patients at risk of developing acquired 
resistance is warranted to better define the role of TMZ in LGG.  
 
KEYWORDS: Low-Grade Glioma, Temozolomide, Resistance, Tumor Growth Inhibition, 
Mathematical Model. 
 
INTRODUCTION 
 
Adults’ diffuse low-grade glioma (LGG) is a primary brain tumour. LGGs account for about 
25% of gliomas and are characterized radiologically by slow and continuous growth 
preceding anaplastic transformation [1]. However, despite surgery, radiotherapy and 
chemotherapy, most tumours recur and remain incurable with a median survival of 5 to 15 
years. Among chemotherapeutic treatments, temozolomide (TMZ), an alkylating agent, has 
improved the prognosis of glioblastomas, especially in tumours that have a methylated 
MGMT promoter and therefore cannot repair TMZ-induced DNA damages [2]. In LGG, 
however, despite the presence of a methylated MGMT promoter in most patients, the benefit 
of TMZ remains unclear [3]. Growth kinetic studies have shown that TMZ most frequently 
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results in an initial volume decrease but that this effect is rarely long lasting with most 
patients developing tumour progression either during or shortly after TMZ disruption [4]. In 
addition, mutational analyses in recurrent LGG have demonstrated that, in a subset of 
patients, TMZ leads to the acquisition of a hypermutation phenotype which is associated with 
increased mitotic activity and could contribute to malignant progression through mutations in 
the RB and AKT-mTOR pathways [5]. This phenomenon is thought to result from 
inactivating mutations of the DNA mismatch repair (MMR) pathway which has been shown 
to be a mechanism of acquired resistance to TMZ, especially in gliomas with a methylated 
MGMT promoter [6-10]. Therefore, in a subset of LGG, the mutagenic effect of TMZ could 
induce inactivating mutations in MMR genes resulting in acquired resistance to TMZ and in a 
detrimental hypermutation phenotype as a result of continued TMZ exposure [6].  
Mechanisms of LGG resistance to TMZ remain unclear, although we can suppose that two 
types of resistance exist: i) primary resistance and ii) acquired resistance. Primary resistance 
may correspond to natural tumour capacity to resist to treatment damages, such as p53 
mutation and MGMT hypermethylation. As for acquired resistance, it corresponds to genetic 
and epigenetic changes in neoplastic cells initially sensitive to treatment. Acquired resistance 
arises with TMZ treatment, and can be linked to MGMT production increase [11], or to new 
mutations appearing after TMZ onset [5, 7]. Nevertheless, these hyper mutated recurrent 
cancer cells are not observed in all patients treated with TMZ, and there is currently no 
available pre-TMZ treatment biomarker that can help to prevent this emergence of resistance. 
Understanding how LGG develop resistance to treatment is therefore a major issue.  
Our aim herein is to propose a semi-mechanistic model, describing the different processes of 
emergence of resistance for LGG treated with TMZ. In this view, our mathematical model 
distinguishes between sensitive cells, primary resistant cells and cells becoming resistant due 
to exposure to treatment. We furthermore present a statistical population mixture model that 
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allows to determine if a given patient developed acquired resistance or not. Associations 
between predicted resistance profiles, LGG molecular characteristics and outcome are then 
studied. In order to explore whether the resistance profile might be different in patients 
treated with PCV chemotherapy (Procarbazine, CCNU, Vincristine), another chemotherapy 
regimen used in LGG, a subset of patients who received this treatment is also analysed.  
 
MATERIAL AND METHODS 
 
Data 
 
We analysed longitudinal follow-up of tumour size measurements in 121 patients treated with 
upfront chemotherapy (109 patients with TMZ, 12 patients with PCV) and in whom time-
course of tumour size was available before, during and after treatment [12]. Tumour sizes 
were expressed as mean tumour diameters (MTD) estimated from magnetic resonance 
imaging (MRI) [12]. MRIs were performed every 4 to 6 months before and after treatment. 
During the treatment, MRIs were performed every 3 months.  For each patient, 12 MRI were 
performed on averaged, with at least 2 MRI before treatment onset and 4 after. One TMZ 
cycle corresponds to a daily administration of 200 mg/m2 of TMZ for five consecutive days. 
Patients included in the study received one cycle of TMZ per month for up to two years. PCV 
administration protocol consists of up to 6 cycles, with intervals of 6 weeks between cycles: 
CCNU (110 mg/m2) administered on day 1, procarbazine (60 mg/m2) administered on days 8 
to 21, and vincristine (1.4 mg/m2, max. 2 mg) administered on days 8 and 29.  
In most patients, TMZ resulted in an initial reduction in tumour size, which was followed by 
tumour regrowth either during treatment or after TMZ administration. Figure 1 displays three 
different individual profiles that are observed in our population of patients treated with TMZ, 
where duration of treatment is represented with the grey shaded area. The left graph 
represents an example of a patient who experienced tumour progression during treatment. For 
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the two other patients, the tumour regrows immediately after treatment disruption (middle 
graph) and after a certain time (right graph). Note that no tumour regrowth during PCV 
treatment was observed, but rather a prolonged response for several months after cessation of 
treatment.  
In addition to tumour size measurements, data on survival and genetic information were also 
available for patients treated with TMZ. Progression-free and overall survivals were 
computed as the time between treatment onset and clinical progression or death respectively. 
Patients lost to follow-up were censored at the time of last news. For 71 out of the 109 
patients treated with TMZ, the following molecular characteristics were available: 1p/19q 
chromosomal co-deletion, p53 overexpression, and IDH mutation status. MGMT promoter 
methylation was available in 53 patients.  
 
Mathematical models for resistance in low-grade gliomas treated with chemotherapy  
 
We first developed two models describing each of them a different resistance profile. The 
first model, called model PR, describes LGG dynamics assuming there are only primary 
resistant cells. The second model, called model PAR, describes LGG dynamics assuming 
both primary and acquired resistant cells are present in the tumour. These two models are 
schematically represented in Figure 2.  
For model PR, we assume that the tumour is initially composed of sensitive cells, denoted S 
and primary resistant cells, denoted RP. During treatment, chemotherapy induces DNA 
lesions to sensitive cells only. They then become damaged cells (denoted D) with a rate 
τSDC(t), where C(t) is the chemotherapy blood concentration. Damaged cells eventually die 
with a rate μD. We assume that sensitive and primary resistant cells proliferate with the same 
growth rate λ. Mathematical formulation of this model is as follows:  
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dS
dt
=λ × S × 1 − P
PR
120
 
 
 
 
 
 −τ SD × C t( ) × S with S(0) = ks × P0
dD
dt
=τ SD × C t( ) × S − μD × D with D(0) = 0
dRP
dt
=λ × RP × 1 −
PPR
120
 
 
 
 
 
 with RP(0) = 1 − kS( )× P0
 
 
 
 
 
 
 
 
 
(A) 
 
where PPR = S + D + RP is the total tumour size,  P0 is the initial mean tumour diameter and 
kS represents the initial proportion of sensitive cells in the tumour. The tumour is assumed to 
grow according to a logistic model with maximal tumour size fixed to 120 mm, a choice 
consistent with the maximal tumour size observed in clinical practice [4].  
 
For TMZ, blood concentration C is supposed to follow a mono-compartmental kinetic [13]:  
C(t) =
D × ka
V × ka −Cl
e
−
Cl
V
(t −td )+ − e−ka t −td( )+
 
 
 
 
 
 
d =1
ND

 
where ka , Cl , and V are, respectively, the absorption coefficient, the clearance, and 
the volume of distribution of TMZ. Other ways to implement TMZ concentration would have 
been possible. For example, the TMZ concentration could have been supposed to be constant 
during the treatment period. However, this hypothesis seemed to us less realistic than to use a 
previously published PK model to simulate TMZ concentrations. In addition assuming a 
continuous TMZ concentration may have introduced a bias in parameters estimate. For PCV, 
we did not model the three drugs separately. Following the work of Ribba et al. [14], we 
defined PCV’s concentration C( t) as a unique variable representing a virtual drug 
administrated intravenously at a dose D fixed to 1: 
C( t) = t − td( )+ × e
−ke t −td( )+
d =1
ND
  
where ke is the rate of decay of PCV concentration.  
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For model PAR, we assumed that resistant cells emerge due to exposure to chemotherapy, in 
addition to pre-existing resistant cells. As in model PR, the tumour is initially composed of 
sensitive cells S and primary resistant cells RP, only sensitive cells being affected by the 
treatment. However, in this model, damaged cells D can either die with a rate μ
 
or become 
resistant with a rate τDR due to new mutations for instance. These resistant cells, denoted RA 
in the model, proliferate at a rate λR. Mathematical formulation is as follows:  
 
dS
dt
=λ × S × 1 −
PPAR
120
 
 
 
 
 
 −τ SD × C t( ) × S with S(0) = ks × P0
dD
dt
=τ SD × C t( ) × S − τ DRA + μD( )× D with D(0) = 0
dRA
dt
=λ × 1 + ΔRA( )× RA × 1 − P
PAR
120
 
 
 
 
 
 +τ DRA × D with RA(0) = 0
dRP
dt
=λ × RP × 1 −
PPAR
120
 
 
 
 
 
 with RP(0) = 1 − kS( )× P0
 
 
 
 
 
 
 
 
 
 
 
 
 
(B)
 
where PPAR = S + D + RP + RA represents the total tumour size. Because TMZ can induce 
malignant transformation, and thus faster tumour growth [5], we further assumed that 
acquired resistant cells divide at a rate that could be greater than or equal to λ. Therefore we 
set λR = λ(1+∆R), with ∆≥0. Blood concentration of chemotherapy is modelled as described 
above.  
 
Population Mixture Model 
 
As hypermutation phenotype was not clinically observed in all patients treated with TMZ, we 
could assume that tumours can, but do not necessarily develop acquired resistance. Instead of 
describing all patients with either model PR or model PAR, it could be interesting to 
determine which model is more suitable for a given patient. Resistance profile (PR or PAR) 
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is therefore viewed as an unknown status to determine, as we do not know a priori which 
resistance profile corresponds the best. We thus introduced a population mixture model, 
allowing to describe both profiles within the same framework, and to classify patients in one 
or the other resistance profile.  
Let us denote by yij tumour measurement at time tij for the i-th patient and φi  its individual 
parameters. We introduce a Between Subject Model Mixture (BSMM) describing tumour 
observations as follows [15]: 
yij = P
PAR tij ,φi( )+ ε ij with Pr G i = PAR( ) = π PAR
yij = P
PR tij ,φi( )+ ε ij with Pr G i = PR( ) = 1 − π PAR
 
 
 
  
(C)
 
Where Gi is the resistance profile of patient i, P
PR and PPAR are the tumour size obtained with 
models (A) and (B) respectively. Residual errors ε ij  are assumed to be normally distributed 
with mean equal to 0, and standard deviation equal to σ. To summarize equation (C), the 
BSMM assumes that the growth curve of each subject follows one of the two previously 
described models (PR or PAR) but without knowing which one a priori. The proportion of 
the population associated to each of the two models is unknown a priori. Each subject has a 
label Gi corresponding to the model from which it has been generated. This label is inferred 
using an estimation algorithm. This estimated label is the used to classify the subjects in the 
two groups. This mixture model enables to describe both patients with primary resistance 
only and patients who develop acquired resistance within the same model. Such statistical 
model has been successfully used to detect non-responder to a given treatment [15,16] or to 
describe complex absorption process [17]. Finally, the vector of individual parameters φi  was 
given by φi = (λi , Δ i ,τ SDi ,τ DRi , μDi , kSi , P0 i ). We assumed that all parameters were log-
normally distributed, except kS that was assumed to follow a logit-normal distribution. 
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Model Development and Evaluation  
 
Model development was based on TMZ data set as the model’s hypothesis are based on 
biological results obtained from patients treated with TMZ. During this first step, we 
determined which model structure best fitted the data between PPR, PPAR, or BSMM. Once a 
model’s structure was selected, final estimates were obtained using TMZ and PCV data sets 
that had been pooled together to study potential differences between TMZ- and PCV-treated 
patients. 
Population parameters were estimated using the SAEM algorithm [18] implemented 
in the Monolix software [19]. Model evaluation and selection were based on the visual 
inspection of the goodness of fit plots, precision of parameter estimates and a decrease in 
Bayesian Information Criterion (BIC). Shrinkage of individual random effects and residual 
error was also assessed [20]. The goodness of fit was established by plotting the population 
predictions of the model vs. observations, individual predictions vs. observations and visual 
predictive check. All graphics were generated using the package ggplot2 [21] with R 
software [22]. 
 
Analysis of Clusters’ Characteristics for patients treated by TMZ 
 
When considering the mixture model, each patient is assigned to a cluster. Patients' 
characteristics of both clusters are compared using a Student test for continuous variables and 
a chi-squared test for categorical ones. Progression-free survival (PFS) and overall survival 
(OS) are studied using the Kaplan-Meier method. Difference between PFS and OS in both 
clusters is assessed using a Log-Rank test. A multivariate survival analysis is conducted 
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using a Cox proportional hazard model to adjust for age, mutation status and tumour size at 
TMZ onset. Statistical significance of each variable is assessed using a Wald test.  
 
RESULTS 
 
Model development and evaluation 
 
We first studied whether resistance to TMZ most likely results from primary resistance only 
(model PR) or from primary and acquired resistance (model PAR). For this purpose, we 
independently estimated parameters of models PR and PAR on the TMZ data set only. 
Parameter τSD , standing for the rate of transition from sensitive cells to damaged ones, was 
considered as fixed effect since it improved the quality of parameter estimates and had no 
impact on the goodness of fit plots. Moreover it prevents identifiably issues due to the lack of 
pharmacokinetic data. We found that model PAR performs better than model PR (BIC=7489 
compared to 7670 with model PR), showing that taking into account the two types of 
resistance more accurately describes experimental data than taking into account primary 
resistance only. 
 However, because all tumours do not exhibit hyper mutation phenotype after TMZ 
treatment [5], and therefore may not develop acquired resistance, we investigated whether 
model PAR is suitable for all patients. For this purpose, we estimated parameters of the 
mixture model, which allows patients to be described either with model PR or with model 
PAR. This latter yielded to even better results suggesting that resistance to TMZ in LGG is 
variable, resulting from primary resistance only in some patients and from both (primary and 
acquired resistance) in others. The BSMM mixture model improved data fitting as 
demonstrated by the decrease of BIC value (BIC =7466 for BSMM), and led also to a more 
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accurate parameter estimates and a decrease of variances of random effects. Shrinkage values 
for parameters τDR  and ΔR remained high (between 45% and 60%), indicating an identifiably 
issue in individual random effects. In consequence, no inter-individual variability was 
allocated to these two parameters. It improved shrinkage values and precision of parameter 
estimates. 
After having identified the BSMM model as the model that best fits data in LGG 
patients treated with upfront TMZ, we estimated parameters of the BSMM model using the 
whole dataset of patients (i.e including also patients treated with upfront PCV 
chemotherapy). Population parameter estimates (mean value and inter-individual variability) 
are presented in Table 1. Note that as ΔR was estimated different to zero, it implies a faster 
proliferation of acquired resistant cells, which support the hypothesis of increased mitotic 
activity. All parameters were accurately estimated with residual standard errors smaller than 
25%. Highest shrinkage value of individual random effects was 31%. Shrinkage value of 
residual errors was 14% indicating good identifiably of the proposed model. Individual 
parameters were then estimated. In the same time, the 121 patients were classified into one of 
the two clusters, according to the mechanism of resistance (primary resistance only or 
primary and acquired resistance) most likely to explain their individual tumour growth 
dynamics. Among patients treated with upfront TMZ, 56 patients (51%) were assigned to 
PAR cluster (primary and acquired resistance) and 53 patients (49%) to PR cluster. In 
contrast, all patients treated with upfront PCV were assigned to PR cluster. 
Model validation was then performed using observed versus predicted plots and 
Visual Predictive Check (VPC). The are presented in Figure 3 and Figure 4. Concerning VPC 
plots in TMZ treated patients, left plot represents VPC for PR cluster, while right plot is VPC 
for PAR cluster. Data fall into confidence intervals for both clusters, indicating good 
properties of the population model. Tumour regrowth occurs sooner in the PAR cluster, and 
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tumour size increases faster after TMZ onset. For both cluster, the 95-th quantiles seem to 
over predict tumour re-growth. This phenomenon is partially due to missing information as a 
consequence of an informative censoring process. Indeed, the follow up of most patients 
ended quickly after tumour re-growth because of the initiation of a new therapeutic. 
Figure 5 displays examples of individual fits for patients in each cluster, with 
dynamics of each sub-population of cells. As shown, the model is able to reproduce different 
patterns of growth dynamics in each cluster.   
 
Impact of genetic mutations and survival analysis 
 
There was no significant difference between baseline characteristics of patients clustered in 
PR or PAR profile, including age, tumour size at TMZ onset, sex, p53 expression, IDH 
mutation status, 1p/19q co-deletion status and MGMT methylation status. 
However, their outcome was different (Figure 6). Patients with acquired resistance to 
TMZ have both a shorter median progression free survival (22.7 months (95\% CI = 16.0 to 
28.6) versus 49 months (95\% CI = 37.9 to 57.2), p-value < 0.001) and a shorter median 
overall survival  (50.7 months (95\% CI = 35.3 to 76.4) versus 139.5 months (95\% CI= 86.4 
to not reached), p-value < 0.001) compared to patients without acquired resistance. This 
result is coherent with the model's assumption as acquired resistance enhance tumour growth. 
On multivariate analysis, the impact of acquired resistance to TMZ was independent of age, 
molecular profile (p53 overexpression, IDH mutation and 1p/19q co-deletion) and tumour 
size at TMZ onset (Table 2 and right plot in Figure 6).  
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DISCUSSION 
It has been recently suggested that because of acquired resistance, TMZ may paradoxically 
drive tumour progression in LGG [5-6]. Consistently, in the present study, using 
mathematical modelling, we show that in a subset of LGG, tumour growth dynamics is best 
described by the hypothesis of a detrimental TMZ-induced resistance and that this 
phenomenon is associated with worst outcome independently of classical prognostic factor. 
 
Resistance to treatments is one of the main causes of therapeutic failures in oncology. 
Mathematical modelling has been shown to be an effective strategy to investigate resistance 
mechanisms to chemotherapy and to propose new therapeutic strategies [23-24]. There is a 
long tradition of mathematical modelling of both resistance to chemotherapy and of glioma 
growth; however, to the best of our knowledge, no study has specifically focused on 
modelling resistance to chemotherapy in LGG. Most of the models that have been proposed 
to describe and analyse cancer resistance to chemotherapy have considered the tumour as 
being composed of two cell populations: one population of sensitive cells and one population 
of resistant cells. In the 1980s, [25] first proposed such a model based on ODE. This 
pioneering model effectively accounted for kinetic resistance in breast cancer treated with 
cell cycle phase-specific chemotherapy based on the distinction of sensitive/resistant and 
proliferative/quiescent cells. Thereafter, this framework was widely used to explore different 
hypotheses in cancer resistance such as optimal dosing schedules and the potential 
implications of cancer stem cells in drug resistance [23,26]. However, these models were not 
developed to explicitly differentiate primary from acquired resistance. For this purpose, 
Komarova et al [27] proposed a discrete space markov process; but, this model was not 
calibrated using clinical data, and may be computationally very demanding. Terranova et al 
[28] proposed an ODE model incorporating different resistant cell subpopulations allowing 
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the description of both primary and acquired resistance. Here again, the model was not 
calibrated using real data. Finally, in the specific context of LGG, Mazzocco et al [29] 
developed a tumour growth inhibition model of LGG treated with TMZ, in which parameters 
were estimated using longitudinal tumour size measurements. In this model, however, 
resistance to TMZ was described using an empirical parametric function, giving no insight on 
resistance mechanisms, as treatment efficacy was simply considered to decrease with time. 
 
The aim of our study was to develop a model to investigate TMZ resistance in LGG. 
To our knowledge, this is the first study trying to classify patients according to their potential 
resistance mechanisms. For this purpose, we developed a model describing both primary and 
chemotherapy-induced resistance using a data-driven approach. We distinguished different 
cell subpopulations: sensitive cells, primary resistant cells, damaged cells, and cells that 
become resistant after being damaged. After evaluating different models, we found that, in 
agreement with the hypothesis of a detrimental TMZ-driven progression in a subset of 
patients, the model that most accurately described the data was a model considering that 
resistance to TMZ in LGG is heterogeneous, consisting of either primary resistance only or 
primary and acquired resistance contributing to tumour progression. A potential development 
of the model would be to use it to identify patients who may not benefit from TMZ. 
However, in the current version of the model, to accurately classify patients, we need 
observations during and after treatment with TMZ. In order to detect as early as possible 
patients who develop acquired resistance, or even to predict it, we would need to include 
covariates such as p53 mutation, IDH mutations or MGMT promoter hypermethylation in the 
model, particularly on parameter π PAR . In the present study, however, these molecular 
characteristics were not available in every patients making impossible evaluation of these 
covariates according to a mixed model approach. 
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Due to the lack of patients who underwent re-resection after TMZ progression, we 
could not determine whether in recurrent tumours clustered with acquired resistance, features 
suggestive of acquired resistance such as MMR gene mutations or a hypermutation 
phenotype were found. However, our modelling results are supported by striking similarities 
with those of the mutational analysis performed in recurrent LGG after TMZ. These analyses 
have shown that the acquisition of a hypermutation profile after TMZ treatment was only 
observed in a subset of patients (6 out 10 LGG analyzed [5]), was associated with an 
increased mitotic activity, and occurred in both LGG with and without the 1p/19q co- 
deletion [5,30]. Consistently, our model predicted that acquired resistance to TMZ only 
occurred in a subset of patients (56 out of 109 patients), occurred independently of LGG 
molecular characteristics (especially 1p/19q co-deletion) and was associated with a much 
important growth rate during tumour progression. Our modelling results are also indirectly 
supported by the fact that none of the patients treated with PCV chemotherapy were 
classified into the acquired resistance cluster. Indeed, in contrast to TMZ, the effect of 
CCNU, which is a nitrosourea and the main drug of the PCV regimen, is not mediated by the 
MMR pathway. To our knowledge, the genomic profile of recurrent LGG after PCV 
chemotherapy has not been assessed; however, several in vitro studies have shown that in 
contrast to TMZ, an exposure to nitrosoureas does not lead to the acquisition of a 
hypermutation phenotype [31-33]. 
 
TMZ induced-hypermutation phenotype has been suggested to be detrimental but its 
clinical impact has not been studied yet. It would require the analysis of a large number of re-
operated recurrent LGG. Owing to the absence of a biological validation, our model results 
must be taken with caution, although they suggest that TMZ-induced resistance may have a 
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negative clinical impact. Indeed, in our model, predicted acquired resistance was associated 
with shorter overall survival independently of age, tumour size, and of LGG molecular 
characteristics, namely 1p/19q co-deletion. This finding may have important clinical 
consequences. In recent years, upfront chemotherapy with TMZ has been developed as a 
strategy to defer radiotherapy and its potential neurotoxicity in LGG patients. The 
preliminary results of a randomized phase III study comparing initial TMZ versus initial RT 
suggested that this strategy might be effective in 1p/19q co-deleted but not in LGG without 
1p/19q co-deletion [34]. Yet, our modelling results suggest that even in 1p/19q co-deleted 
LGG, TMZ might be detrimental in patients at risk of developing acquired resistance. 
 
Although our modelling results provide original insight into the resistance mechanism 
of LGG after chemotherapy, some points will need to be further investigated. The lack of 
validation of our prediction is the principal limitation of this work. The validation of our 
predictions will need: i) to validate at the biological level that our patients with 
acquired resistance have a hyper mutated phenotype and ii) to validate our model in 
an external dataset. The association with the worst outcome will also need to be validated in 
an independent study. Nevertheless, together with mutational analysis of recurrent LGG after 
TMZ, our study suggests that beyond LGG current molecular classification, the benefit of 
TMZ may depend on the tumour capacity to develop acquired resistance and that 
identification of patients at risk of developing acquired resistance will be important to better 
define the role of TMZ in LGG. 
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Table 1: Estimated values of the population parameter 
 
Population mean 
(% RSE) 
Inter-patient 
variability (% RSE) 
Shrinkage 
(%) 
Tumor Growth 
Parameters 
   
λ  (d-1) 0.000385 (8) 0.745 (9) 0.16 
ΔRA  11 (11) - - 
τSD(L.g-1.d-1) 0.0382 (10) - - 
τDR  (d-1) 0.000544 (24) - - 
μD (d-1) 0.00219 (9) 0.701 (10) 0.27 
kS  0.474 (5) 0.65 (10) 0.31 
P0  (mm) 40 (5) 0.503 (7) 0.01 
Pharmacokinetic 
Parameters of TMZ 
   
ka (d
-1) 140 (fixed) - - 
V (L) 30 (fixed) - - 
Cl (L.d-1) 240 (fixed) - - 
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Pharmacokinetic 
Parameters of PCV 
   
ke 0.025 (fixed) - - 
Mixture Parameter    
π PAR  0.48 (13) - - 
Residual Error 
Parameter 
   
σ 2.31 (2) - 0.14  
λ : division rate of sensitive and primary resistant cells, ΔRA : increase in division rate of 
acquired resistant cells, τSD : transition rate from sensitive to damaged cells, τDR : transition 
rate from damaged to acquired resistant cells, μD: death rate of damaged cells, kS : 
proportion of sensitive cells at the beginning of the follow-up, P0 : initial mean tumor size, ka: 
TMZ absorption rate, V : TMZ volume of distribution, Cl: TMZ clearance,  π PAR : probability 
to belong to the cluster with acquired resistance, σ: residual error standard deviation. 
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Table 2: Multivariate survival analysis using Cox proportional hazard model. 
 
 
Hazard Ratio 95 % Confidence 
Interval 
p-value 
Acquired Resistance 
Cluster 
3.65 1.65 – 8.1 0.00143 
Age  
(year) 
1.032 0.99 - 1.067 0.07 
Tumor Size at TMZ 
Onset  
(mm) 
1.018 0.997 - 1.0385 0.09 
p53 overexpression 1.01 0.42 - 2.43 0.97 
IDH Mutation 1.09 0.47 - 2.51 0.83 
1p/19q 
Chromosomal Co-
deletion 
0.17 0.05 - 0.65 0.009 
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Figure 1 
Observed tumor mean diameter in three patients. Dots represent observed mean tumor 
diameters. Gray shaded intervals correspond to TMZ administration.  
 
Figure 2  
Schematic representation of the two tumor growth inhibition models (left: model with 
primary resistance only, right: model with primary and acquired resistance). LGG cells are 
divided into cells sensitive to TMZ (S), cells damaged by TMZ (D), primary resistant cells 
(RP), and acquired resistant cells produced by chemotherapy exposition (RA). λ : division rate 
of sensitive and primary resistant cells, ΔR: increase in division rate of acquired resistant 
cells, τSD : transition rate from sensitive to damaged cells, τDR : transition rate from damaged 
to acquired resistant cells, μD: death rate of damaged cells, kS : proportion of sensitive cells 
at the beginning of the follow-up. 
 
Figure 3 
Observations versus model predictions (top: population predictions, bottom: individual 
predictions) for each cluster [left: cluster with primary and acquired resistance, middle: 
cluster with primary resistance only (TMZ treated patients), right: cluster with primary 
resistance only (PCV treated patients)]. 
 
Figure 4 
Visual Predictive Check plots in both clusters for TMZ treated patients. Left: Median, 5% 
and 95% quantiles of model simulations for model PR, ie with primary resistance only. Dots 
represent individual data for patients clustered in PR profile. Right: Median, 5% and 95% 
quantiles of model simulations for model PAR, ie with primary and acquired resistant cells. 
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Dots represent individual data for patients clustered in PAR profile. 
 
Figure 5 
Evolution of individual mean tumor diameter simulations in 9 representative patients. Black 
dots correspond to mean tumor diameters. Black curves correspond to simulated mean tumor 
diameters. Green, yellow, light red and dark red curves respectively correspond to sensitive, 
damaged, acquired and primary resistant cells. First row: Patients with primary and acquired 
resistance treated with TMZ. Second row: Patients with primary resistance only treated with 
TMZ. Third row: Patients with primary resistance only treated with PCV. 
 
Figure 6 
Left and middle: comparison of clinical outcomes between patients with and without 
acquired resistance. Red curve corresponds to the group with primary and acquired resistant 
cells (PAR profile). Blue curve corresponds to the group with primary resistance only (PR 
profile). Black marks correspond to censored observations. Left: Kaplan-Meier estimates of 
progression free survival since treatment onset in patients with and without acquired 
resistance. Middle: Kaplan-Meier estimates of overall survival from treatment onset in both 
cluster. Right: Kaplan-Meier estimates of overall survival since treatment onset stratified 
according to 1p/19q chromosomal co-deletion status and resistance clusters for patients 
treated with TMZ. Red survival curve corresponds to the group with primary and acquired 
resistance without 1p/19q chromosomal co-deletion. Green survival curve corresponds to the 
group with primary and acquired resistance with 1p/19q chromosomal co-deletion. Purple 
survival curve corresponds to the group with primary resistance only with 1p/19q 
chromosomal co-deletion. Blue survival curve corresponds to the group with primary 
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resistance only without 1p/19q chromosomal co-deletion.  Black marks correspond to 
censored observations.  
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